What We Do
Founded in 2006 by Dr. Matt Leavitt, Executive Chairman and Founder of Advanced Dermatology and Cosmetic Surgery (ADCS), our Clinical Trial Research Division is dedicated to advancing dermatological practice through innovative research and the development of improved treatments for various skin conditions.
In collaboration with the Arthritis Research Center Foundation, ADCS recently examined patient-reported outcomes and treatment utilization by comparing dermatologist-led and patient-led enrollment in a psoriasis registry. This study, published in the Journal of Psoriasis and Psoriatic Arthritis, highlights our commitment to patient-centered research and the optimization of treatment strategies.
Our researchers have also addressed concerns regarding the impact of COVID-19 on the timely detection and management of melanoma and non-melanoma skin cancers. An elite team from ADCS participated in research published in the Journal of the American Academy of Dermatology (JAAD), contributing valuable insights into maintaining skin cancer care during the pandemic.
Additionally, our team demonstrated the effectiveness of Total-Body Skin Cancer Exams in a study published in the Journal of Clinical Oncology®, an American Society of Clinical Oncology (ASCO) Journal. This research underscores our dedication to comprehensive skin cancer screening and early detection.
By providing access to new drugs and treatments through pharmaceutical and device company-initiated, FDA-supervised clinical trials approved by Institutional Review Boards (IRB), we offer our extensive patient population leading-edge solutions to skin conditions.
Our centralized administrative office ensures uniform methodology, quality assurance, and exemplary data documentation, overseeing contracting and supporting our research endeavors.
The FDA mandates that clinical trial participants receive the highest standard of care, prioritizing safety. Before participation, individuals undergo comprehensive physical exams, including EKGs and blood work, and are closely monitored throughout the trial. This focus on participants' general health may reveal previously undetected health issues, though certain underlying conditions could disqualify individuals from specific trials.
Through these efforts, ADCS exemplifies a commitment to advancing dermatological research and providing patients with innovative, effective treatments.